Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome June 22, 2026 8:30 AM EDT
Company Participants
Hayleigh Collins – Director of Corporate Communications & Investor Relations
Sean Nolan – CEO & Chairman
Sukumar Nagendran – President, Head of Research & Development and Director
Conference Call Participants
Kristen Kluska – Cantor Fitzgerald & Co., Research Division
Salveen Richter – Goldman Sachs Group, Inc., Research Division
Biren Amin – Piper Sandler & Co., Research Division
Tazeen Ahmad – BofA Securities, Research Division
Maurice Raycroft – Jefferies LLC, Research Division
Christopher Raymond – Raymond James & Associates, Inc., Research Division
Jack Allen – Robert W. Baird & Co. Incorporated, Research Division
Jonathan Hsu
Whitney Ijem – Canaccord Genuity Corp., Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Taysha Gene 102 Rett syndrome Program Update Conference Call. [Operator Instructions] Please note that today’s conference is being recorded. I would now like to hand the conference over to your speaker host for today, Hayleigh Collins, Senior Director, Corporate Communications and Investor Relations. Please go ahead.
Hayleigh Collins
Director of Corporate Communications & Investor Relations
Thank you. Good morning, and welcome to Taysha’s TSHA-102 Rett Syndrome Program Update Conference Call. Earlier this morning, we issued a press release announcing the completion of dosing in the REVEAL pivotal trial and longer-term clinical data from Part A of the REVEAL Phase I/II trial evaluating TSHA-102 for the treatment of Rett syndrome.
A copy of this press release is available on the company’s website. Joining me on today’s call are Sean Nolan, Chief Executive Officer; and Su Nagendran, President and Head of R&D. Kamran Alam, Chief Financial Officer, will join us for a question-and-answer session following our prepared remarks.
On today’s call, we’ll be making forward-looking statements, including statements concerning the potential of
